Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)

Arcutis Biotherapeutics, Inc., with its ticker symbol ARQT, is a commercial-stage biopharmaceutical company operating in the dermatological industry. The company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs.

Arcutis Biotherapeutics' main business activities revolve around the identification of molecules against validated biological targets in dermatology, and the development and commercialization of best-in-class products based on those molecules that address significant unmet needs in immuno-dermatology. The company operates primarily in the United States, with its headquarters located in Westlake Village, California.

The company generates revenue through the sale of its primary product, ZORYVE cream, a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. ZORYVE cream is approved by the FDA for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The company's revenue generation strategy also includes expanding the addressable market with potential additional foam indications and establishing an integrated development and commercial organization.

In terms of its competitive position, Arcutis Biotherapeutics is a leading player in the dermatological industry, with a strong pipeline of products and a leading platform for dermatology product development. The company's competitive advantages include its innovative topical cream and foam formulations of roflumilast, its pharmacokinetic characteristics relating to improving delivery and extending half-life of both the cream and foam formulations of topical roflumilast, and its novel topical cream without skin-drying surfactants.

The company's customers include dermatologists and other healthcare professionals who treat patients with dermatological diseases, including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis Biotherapeutics works closely with these healthcare professionals to provide them with the information and support they need to use its products effectively.

The company's product portfolio includes several brands, such as ZORYVE cream and ZORYVE foam, a once-daily steroid-free foam formulation of roflumilast, approved by the FDA for the treatment of seborrheic dermatitis in individuals aged 9 years and older. Additionally, the company has two products, ARQ-255 and ARQ-252, containing ivarmacitinib, a JAK1 inhibitor, for the treatment of alopecia areata, chronic hand eczema, and vitiligo.